Identification of distinct plasma biomarker signatures in patients with rapid and slow declining forms of COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 7, Issue 1, 2010, Pages 51-58

  Devanarayan, Viswanath ^a   Scholand, Mary Beth ^b   Hoidal, John ^b   Leppert, Mark F ^b   Crackower, Michael A ^a,c   O'Neill, Gary P ^a,c   Gervais, Francois G ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Biomarker; Plasma; Signature

Indexed keywords

ALPHA FETOPROTEIN; AMYLOID P COMPONENT; ANTITRYPSIN ALPHA; APOLIPOPROTEIN A1; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7; CARCINOEMBRYONIC ANTIGEN; CINTREDEKIN BESUDOTOX; EOTAXIN; FIBRINOGEN; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HAPTOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; THROMBOPLASTIN; THROMBOPOIETIN; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LUNG FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77949417105     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412550903499530     Document Type: Article

References (30)

1. Fabbri LM, Luppi F, Beghe B, Rabe KF. Update in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:1056-1065.
2. Heffner JE. Chronic obstructive pulmonary disease: on an exponential curve of progress. Respir Care 2002;47:586-607.
3. Rennard SI. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest 1998;113:235S-241S.
4. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:26-33.
5. Owens GR. Public screening for lung disease: experience with the NIH Lung Health Study. Am J Med 1991;91:37S-40S.
6. Streitberg B, Rohmel J. Exact distributions for permutations and rank tests: an introduction to some recently published algorithms. Statistical Software Newsletter 1986;12:10-17.
7. Benjamini Y, Hockberg Y. The adaptive control of the false discovery rate in multiple hypotheses testing with independent statistics. J Behav Educ Statist 2000;25:60-83.
8. Venables WN, Ripley BD. Modern Applied Statisitics, Fourth Edition. Springer, New York.
9. Aldonyte R, Eriksson S, Piitulainen E, Wallmark A, Janci-auskiene S. Analysis of systemic biomarkers in COPD patients. COPD 2004;1:155-164.
10. Jahnz-Rozyk K, Chcialowski A, Pirozynska E, Rogalewska A. Expression of adhesion molecules LFA-1 (CD11a and ICAM-1 (CD54) on lymphocytes and chemokines IL-8 and MCP-1 concentrations in bronchoalveolar lavage of patients with asthma or chronic obstructive pulmonary disease. Pol Merkur Lekarski 2000;9:649-652.
11. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-580.
12. Zhang N, Xu Y, Zhang Z, Liu J, Fang H, Ni W. Effects of theo-phylline on plasma levels of interleukin-4, cyclic nucleotides and pulmonary functions in patients with chronic obstructive pulmonary disease. J Tongji Med Univ 1999;19:15-19.
13. Pinto-Plata V, Toso J, Lee K, Parks D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B. Profiling Serum Biomarkers in Patients with COPD: Associations with Clinical Parameters. Thorax 2007;62:595-601.
14. Carpentier I, Coornaert B, Beyaert R. Function and regulation of tumor necrosis factor type 2. Curr Med Chem 2004;11:2205-2212.
15. Foster CA. VCAM-1/alpha 4-integrin adhesion pathway: therapeutic target for allergic inflammatory disorders. J Allergy Clin Immunol 1996;98:S270-S277.
16. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004;56:515-548.
17. Barcelo B, Pons J, Fuster A, Sauleda J, Noguera A, Ferrer JM, Agusti AG. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2006;145:474-479.
18. Jeffery PK. Lymphocytes, chronic bronchitis and chronic obstructive pulmonary disease. Novartis Foundation Symposium 2001;234:149-168.
19. Schwabe RF, Engelmann H, Hess S, Fricke H. Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Exp Immunol 1999;117:153-158.
20. Schmilovitz-Weiss H, Belinki A, Pappo O, Sulkes J, Melzer E, Kaganovski E, et al. Role of circulating soluble CD40 as an apoptotic marker in liver disease. Apoptosis 2004;9:205-210.
21. Mocali A, Cedrola S, Della MN, Bontempelli M, Mitidieri VA, Bavazzano A, Comolli R, Paoletti F, La Porta CA. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp Gerontol 2004;39:1555-1561.
22. Komura K, Fujimoto M, Matsushita T, Yanaba K, Kodera M, Kawasuji A, Hasegawa M, Takehara K, Sato S. Increased serum soluble CD40 levels in patients with systemic sclerosis. J Rheuma-tol 2007;34:353-358.
23. Zvi B, Levy AP. Haptoglobin phenotypes, which one is better and when? Clin Lab 2006;52:29-35.
24. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4124.
25. Balbi B, Bason C, Balleari E, Fiasella F, Pesci A, Ghio R, Fabiano S. Increased bronchoalveolar granulocytes and granu-locyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997;10:846-850.
26. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001;12:297-304.
27. Staub HL, Franck M, Ranzolin A, Norman GL, Iverson GM, von Muhlen CA. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev 2006;6:104-106.
28. Cosio BG, Agusti A. Autoimmunity in chronic obstructive pulmonary disease (COPD). Arch Bronconeumol 2005;41:10-14.
29. Ranes J, Stoller JK. A review of alpha-1 antitrypsin deficiency. Semin Respir Crit Care Med 2005;26:154-166.
30. Yamashita U, Kuroda E. Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol 2002;22:105-114.